Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024 08:00 ET
|
Ikena Oncology, Inc.
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in...
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
February 21, 2024 16:15 ET
|
Ikena Oncology, Inc.
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy...
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
January 18, 2024 16:05 ET
|
Ikena Oncology, Inc.
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core...
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
November 09, 2023 07:00 ET
|
Ikena Oncology, Inc.
Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment...
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
November 07, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Ikena Oncology to Participate in September 2023 Investor Conferences
September 05, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
August 10, 2023 08:00 ET
|
Ikena Oncology, Inc.
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by...
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
August 07, 2023 07:00 ET
|
Ikena Oncology, Inc.
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO,...